MC Sciences Information

Built from Survival. Driven by Science. Focused on Patients. MC Sciences is an emerging biotechnology company developing first-in-class superior therapeutics that target mast cells in several high-need diseases. The company’s scientific platform is built on the novel discovery of a unique mast cell receptor that controls the entire mast cell activity unlocking the potential for transformative treatments with superior efficacy and a strong safety profile. This scientific breakthrough enables the development of novel therapeutics tailored to address specific unmet needs of several major disease areas in dermatology, respiratory, gastroenterology, fibrotic diseases, chronic inflammation disorders and neuroinflammation. 3 Key Factors That Differentiates MC Sciences 1) First-in-class based on novel discovered biology 2) Expected superior therapeutic profile with unique complete silencing selectively of mast cells contributing to the disease 3) In-human validated pharmacology with expected high probability for clinical success Therapeutic Focus of MC Sciences Major diseases with high need as chronic urticaria, systemic mastocytosis, food allergy, allergic asthma, chronic inflammation disorders (such as MCAS, fibromyalgia, IBS, long covid and chronic lyme), COPD, pulmonary and liver fibrosis. Strong Leadership and Team Capabilities MC Sciences was founded by Prof. Gerhard J. Molderings together with founding CEO Wolfgang Taumann who created and built the scientific foundation of MC Sciences and established a strong leadership team. MC Sciences is now driven by CEO Dr. Michael Mark, an industry leading drug-maker with blockbuster track record, together with a strong team of leading drug development, science and medical experts, and guided by board chairman Dr. Mikael Dolsten to advance MC Sciences towards clinics. MC Sciences is headquartered in Munich, Bavaria, Germany and backed by an international consortium of top tier life sciences investment firms.